Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Merck: As The Sun Rises For Keytruda, It Sets For Zetia/Vytorin

Executive Summary

Merck’s focus has shifted increasingly to Keytruda and immuno-oncology, while the company’s older stalwarts like Zetia, Vytorin and Januvia face pressure.


Related Content

Stockwatch: An Earnings Season Renaissance Fades
Merck Says PD-L1 Testing Already On The Rise, Setting Stage For First-Line Launch
Merck/Pfizer's Latest SGLT-2 Data Support Attractive Ertugliflozin/Januvia Combo


Related Companies